Supplementary



Figure S1 Study schema of neoadjuvant/adjuvant resectable PDAC platform trial. This is a single institution open label, Phase II clinical trial testing novel immunotherapy combinations in the neoadjuvant and adjuvant setting. Patients with newly diagnosed, untreated, and surgically resectable PDAC planned for a pancreatectomy were eligible to participate in this investigation. Enrolled patients received one cycle of novel immunotherapy 2 weeks prior to surgical resection. Following surgical recovery, they received an additional cycle of immunotherapy followed by standard of care chemotherapy +/– radiation. They then received an additional 4 cycles of immunotherapy afterwards. Subjects will undergo research blood collections and radiologic imaging for disease monitoring before cycle 1, before surgery, before cycle 2, before adjuvant chemotherapy, before cycle 3, after cycle 6, and then every 3 months (±2 weeks) until 24 months from surgery. After 24 months, subjects will continue with follow-up scans per standard of care practice, approximately every 6 months (±1 month). PDAC, pancreatic ductal adenocarcinoma.

https://dx.doi.org/10.21037/apc-24-2